Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
Type:
Grant
Filed:
February 11, 2022
Date of Patent:
October 24, 2023
Assignee:
Bristol-Myers Squibb Company
Inventors:
Aaron Yamniuk, Mary Struthers, Stanley R. Krystek, Jr., Akbar Nayeem, Ginger Rakestraw
Abstract: The present invention relates to heterodimeric Relaxin fusion polypeptides, in particular to heterodimeric Relaxin 2 fusion polypeptides and uses thereof. Thus, the invention provides Relaxin fusion polypeptides, nucleic acid molecules, vectors, host cells, pharmaceutical compositions and kits comprising the same and uses of the same including methods of treatment. The polypeptides and compositions of the invention may be useful, in particular, in the treatment of cardiovascular diseases, for example for the treatment of heart failure.
Type:
Grant
Filed:
June 16, 2021
Date of Patent:
October 24, 2023
Assignee:
MEDIMMUNE LIMITED
Inventors:
Isabelle Sermadiras, Monika Anna Papworth, Judy Christiane Paterson, Esther Marie Martin, Peng Ke
Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
Type:
Grant
Filed:
January 31, 2022
Date of Patent:
October 3, 2023
Assignee:
Bristol-Myers Squibb Company
Inventors:
Aaron Yamniuk, Mary Struthers, Stanley R. Krystek, Jr., Akbar Nayeem, Ginger Rakestraw
Abstract: Provided herein are monoclonal antibodies that specifically bind to melanin. The antibodies may be chimeric or humanized. Also provided herein are methods of use and methods of making the antibodies described. For example, the melanin antibodies may be used therapeutically to treat or prevent melanoma.
Abstract: Provided are a modified mesenchymal stem cell and culture supernatant thereof, and a pharmaceutical composition comprising said cell or culture supernatant thereof. The mesenchymal stem cell is capable of expressing: (1) a first protein, which is selected from FGF21 or a variant thereof, or a first fusion protein comprising the FGF21 or the variant thereof and (2) a second protein, which is selected from GLP-1 or a variant thereof or a second fusion protein comprising the GLP-1 or the variant thereof. Also provided is the use of the modified mesenchymal stem cell and culture supernatant thereof, and the pharmaceutical composition comprising said cell or culture supernatant thereof in the treatment of metabolic diseases and in the preparation of a medicament for treating metabolic diseases.
Abstract: The present invention relates to an immunogenic fragment peptide of an EN2 protein or an antibody composition specifically recognizing the same. In the present invention, EN2 protein can be quantified through a method of specifically recognizing the peptide. Also, an antibody prepared using the peptide has vastly superior detection sensitivity compared to existing EN2 protein antibodies and thus can be useful in a diagnostic agent for diagnosing prostate cancer.
Type:
Grant
Filed:
December 16, 2021
Date of Patent:
September 5, 2023
Assignee:
SUNG KYUN BIOTECH CO., LTD.
Inventors:
Kyeong-Nam Yu, Eun-Yi Cho, Seung-Hee Chang, Seon-Hee Kim, Hyun-Suk Kim, Ki-Moon Park
Abstract: The present invention relates to an immunogenic fragment peptide of an EN2 protein or an antibody composition specifically recognizing the same. In the present invention, EN2 protein can be quantified through a method of specifically recognizing the peptide. Also, an antibody prepared using the peptide has vastly superior detection sensitivity compared to existing EN2 protein antibodies and thus can be useful in a diagnostic agent for diagnosing prostate cancer.
Type:
Grant
Filed:
December 16, 2021
Date of Patent:
August 22, 2023
Assignee:
Sung Kyun Biotech Co., Ltd.
Inventors:
Kyeong-Nam Yu, Eun-Yi Cho, Seung-Hee Chang, Seon-Hee Kim, Hyun-Suk Kim, Ki-Moon Park
Abstract: The present invention relates to a method for prediction of response to cardiovascular regeneration comprising the use of biomarkers. Further, the present invention relates to a combination of the biomarkers for use in a method for prediction of response to cardiovascular regeneration, a computer device to perform a method according to the present invention and a device adapted for carrying out the inventive method.
Type:
Grant
Filed:
July 16, 2018
Date of Patent:
August 1, 2023
Assignee:
Universität Rostock
Inventors:
Gustav Steinhoff, Julia Nesteruk, Markus Wolfien
Abstract: The disclosure provides an ex vivo method to prepare regulatory T cells, a population of regulatory T cells with enhanced properties and methods of using the population or complexes useful to induce Tregs in a mammal. The ex vivo methods allows for the generation and expansion of super regulatory T cells for the prevention, inhibition or treatment of autoimmune disorders.
Type:
Grant
Filed:
May 11, 2018
Date of Patent:
July 18, 2023
Assignee:
University of Massachusetts
Inventors:
Gregory N. Tew, Lisa M. Minter, Emrah Ilker Ozay
Abstract: A vaccine construct comprising an antigenic PCSK9 peptide and an immunogenic carrier, and methods of using the same that are effective to lower blood cholesterol levels in a mammal and treat dyslipidemias and related disease states in a mammal without the frequency of administration required by passive immunity strategies.
Type:
Grant
Filed:
January 22, 2021
Date of Patent:
July 11, 2023
Assignees:
THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES, UNM RAINFOREST INNOVATIONS
Inventors:
Alan Remaley, John T. Schiller, Marcelo Amar, Bryce Chackerian
Abstract: The present invention relates to new CD22 Chimeric Antigen Receptors (CD22 CAR), an engineered immune cell endowed with said new CD22 CAR and comprising at least inactivated TRAC gene for use in therapy. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.
Type:
Grant
Filed:
March 30, 2018
Date of Patent:
July 4, 2023
Assignee:
CELLECTIS SA
Inventors:
Cecile Schiffer-Mannioui, Philippe Duchateau, Anne-Sophie Gautron
Abstract: Compositions and methods for treating rheumatoid arthritis and/or accelerated atherosclerosis are provided, including an inhibitor of oxidized or malondialdehyde-modified low density lipoprotein (LDL) for administration to a subject. Exemplary inhibitors of oxidized LDL include an anti-oxidized LDL antibody, which results in a reduction in the secretion of pro-inflammatory cytokine from primary monocyte in vitro and the plasma cytokine level of inflammatory cytokine in vivo.
Type:
Grant
Filed:
May 29, 2019
Date of Patent:
July 4, 2023
Assignee:
Abcentra, LLC
Inventors:
Bertrand C. Liang, Stacey Ruiz, Christopher John Farina
Abstract: Provided herein are tumor-antigen VGLL1 specific peptides. Also provided herein are methods of generating VGLL1-specific T cells and their use for the treatment of cancer. In addition, the VGLL1-specific peptides may be used as a vaccine.
Type:
Grant
Filed:
October 5, 2017
Date of Patent:
June 27, 2023
Assignee:
Board of Regents, The University of Texas System
Abstract: The present invention provides novel bispecific antibodies that bind to human CD30 and uses thereof. Methods of treating cancer using the bispecific antibodies described herein are also provided.
Type:
Grant
Filed:
September 24, 2019
Date of Patent:
June 6, 2023
Assignees:
Medical College of Wisconsin, Inc., University of Virginia Patent Foundation
Inventors:
Jeffrey A. Medin, Lawrence G. Lum, Robyn A. A. Oldham, Archana Thakur
Abstract: The purpose of the present invention is to provide an antibody that can be expected to have a therapeutic effect in autoimmune diseases and anticancer treatment by inhibiting S1P transport by SPNS2 to thereby inhibit lymphocyte migration. The present invention is an SPNS2 neutralizing antibody or a fragment thereof, or a derivative thereof, that specifically binds to vertebrate SPNS2 and has lymphocyte migration inhibitory activity through SW transport inhibition.
Abstract: The present invention provides novel IL-12 Fc fusion proteins, methods of making and using the same. The IL-12 Fc fusion proteins are useful for treatment of cancer and can be used in combination with checkpoint blockade.
Type:
Grant
Filed:
August 11, 2022
Date of Patent:
May 23, 2023
Assignee:
Xencor, Inc.
Inventors:
Matthew Bernett, John R. Desjarlais, Rajat Varma, Ke Liu, Nargess Hassanzadeh-Kiabi, Rumana Rashid
Abstract: The present invention provides apelin receptor (APLNR) modulators that bind to APLNR and methods of using the same. The invention includes APLNR modulators such as antibodies, or antigen-binding fragments thereof, which inhibit or attenuate APLNR-mediated signaling. The invention includes APLNR modulators such as antibodies, or antibody fusion proteins thereof, that activate APLNR-mediated signaling. According to certain embodiments of the invention, the antibodies or antigen-binding fragments or antibody fusion proteins are fully human antibodies that bind to human APLNR with high affinity. The APLNR modulators of the invention are useful for the treatment of diseases and disorders associated with APLNR signaling and/or APLNR cellular expression, such as cardiovascular diseases, angiogenesis diseases, metabolic diseases and fibrotic diseases.
Type:
Grant
Filed:
February 4, 2021
Date of Patent:
May 9, 2023
Assignee:
Regeneran Pharmaceuticals, Inc.
Inventors:
Panayiotis Stevis, Andrew J. Murphy, Jesper Gromada, Yonaton Ray, Jee H. Kim, Ivan B. Lobov
Abstract: The invention relates to monoclonal antibodies which specifically bind to the TRBV9 family of human T-cell receptors. The invention also relates to a nucleic acid which codes for said antibody or for an antigen-binding fragment thereof, to an expression vector, to a method for producing the antibody, and to the use of said antibody for treating diseases or disorders associated with the family of human T-cell receptors. The invention is directed towards producing antibodies that can be used for eliminating T-cells carrying T-cell receptors of the TRBV9 family, in particular for treating ankylosing spondylitis, coeliac disease, and blood cancers, in the pathogenesis of which T-cell receptors of the TRBV9 family are involved.
Type:
Grant
Filed:
December 25, 2018
Date of Patent:
March 7, 2023
Inventors:
Olga Vladimirovna Britanova, Mark Aleksandrovic Izraelson, Sergey Anatolievich Lukyanov
Abstract: The present invention provides novel antibodies and antigen binding fragments thereof that bind to human CD30. Also presented are single chain variable antibodies, chimeric antigen receptors and uses thereof. Methods of treating cancer are also disclosed.
Type:
Grant
Filed:
September 24, 2019
Date of Patent:
February 21, 2023
Assignees:
Medical College of Wisconsin, Inc., University of Virginia Patent Foundation
Inventors:
Jeffrey A. Medin, Mary L. Faber, Everett R. Tate, Robyn A. A. Oldham